MiQuant® AAV kits - coming soon
- Fast and easy workflow
- Quantitation independent of AAV serotype
- No DNA extraction required
- Designed for QIAcuity platform
- In-Process Control and Release Testing
- Quantitation without standard curve or further calculations
- Lyophilised kit components simplify logistics and storage
Gene therapy represents one of the most ground-breaking advancements in
modern medicine that has rapidly evolved over the last years leading to
improved methods of applications. Adeno-associated virus (AAV) vectors
are among the most prominent viral vectors for in vivo gene
therapy that target the healthy gene material to the correct location in
the organism which enables the mutated gene to be exchanged by the
healthy one.
Viral genome titre is a critical quality attribute in
AAV characterization for safe and efficacious gene therapy products.
Specificity of AAV vectors as well as the concentration of the vector
titre must be determined throughout the production process and for final
release testing.
The MiQuant® AAV kits have been developed for the
determination of AAV vector titre. Different kit versions enable the
specific detection of AAV genotype 2/6 (including genotype 1, 3 & 7)
or genotype 5
.
If you cannot find the answer to your problem then please contact us or telephone +44 (0)1954 210 200